CAS: 785804-17-3; Abarelix Acetate

主要参考文献

1: Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in- class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2(6):677-96. doi: 10.2217/14796694.2.6.677. 8(6):663-5. doi: 10.1188/04.CJON.663-669. 4(3):161-6. doi: 10.2165/00126839-200304030-00004. 104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. 5(10):2171-9. doi: 10.1517/14656566.5.10.2171. 2(4):209-11. doi: 10.1016/s1540-0352(11)70046-4. 2(5):579-85. 23(1):78. doi: 10.1177/0897190009360369. Abarelix Study Group. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anticancer Drugs. 2006 Oct;17(9):1075-9. doi: 10.1097/01.cad.0000231476.84782.55. 46(1178):22-3. 165(5):1585-9. 73(4):304-11. doi: 10.1016/s0009-9236(02)17637-5. Abarelix Study Group. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology. 2003 Nov;62(5):877-82. doi: 10.1016/s0090-4295(03)00656-3. 110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16. 44(5):495-502. doi: 10.1177/0091270004264920. Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001 Nov;58(5):756-61. doi: 10.1016/s0090-4295(01)01342-5. 169(5):1738-41. doi: 10.1097/01.ju.0000059584.47272.9d. 63(2):342-7. doi: 10.1016/j.urology.2003.09.045. 4(3):275-7. Abarelix Study Group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002 Apr;167(4):1670-4. doi: 10.1097/00005392-200204000-00021.